Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BICO Group AB Class B ( (SE:BICO) ) has shared an update.
BICO Group AB reported a significant decline in net sales and organic sales growth for the first half of 2025, primarily due to macroeconomic challenges such as NIH funding cuts and tariff issues. Despite these challenges, the company strengthened its balance sheet by divesting MatTek and Visikol to Sartorius for USD 80 million. The company is implementing leadership and process changes in its lab automation business to meet the high demand for Biosero’s solutions, aiming to capitalize on growth opportunities in this market.
More about BICO Group AB Class B
BICO Group AB is a company operating in the life sciences industry, focusing on providing solutions for bioprinting, biosciences, and bioautomation. The company aims to enhance research and development processes in academia and industry by offering innovative technologies and services.
Average Trading Volume: 137,359
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.49B
For a thorough assessment of BICO stock, go to TipRanks’ Stock Analysis page.